DIMETHYL FUMARATE — Medical Description

Therapeutic Category: Disease-Modifying Therapy (DMT) | Immunomodulatory Agent

Active Ingredient: Dimethyl fumarate

Dosage Form: Oral delayed-release capsules

Common Strengths: 120 mg and 240 mg, depending on the marketed product.

Medical Description

Dimethyl fumarate is an oral disease-modifying medication used to treat adults with relapsing forms of multiple sclerosis (MS), a chronic neurological disorder that affects the central nervous system, including the brain, spinal cord, and optic nerves.

It has immunomodulatory and anti-inflammatory effects that help reduce disease activity and protect against inflammatory damage to nerve tissue. In appropriately selected patients, treatment can reduce the frequency of MS relapses and the development of new or enlarging lesions detected by magnetic resonance imaging (MRI).

Dimethyl fumarate is not a cure for multiple sclerosis; however, it can help control disease activity and support long-term disease management under specialist supervision.

Indications and Potential Benefits

Dimethyl fumarate is indicated for the treatment of adults with relapsing forms of multiple sclerosis, including:

• Clinically isolated syndrome (CIS): An initial episode of neurological symptoms suggestive of inflammatory demyelination.
• Relapsing-remitting multiple sclerosis (RRMS): A form of MS characterized by episodes of neurological worsening followed by periods of recovery.
• Active secondary progressive multiple sclerosis (SPMS): A progressive stage of MS in which inflammatory disease activity, including relapses, may continue.

Potential clinical benefits include:

• Reduction in the frequency of clinical relapses.
• Reduction in the development of new or enlarging brain lesions on MRI.
• Reduction in inflammatory disease activity.
• Support for long-term management of relapsing multiple sclerosis.

The exact approved indications depend on the applicable national product labeling.

Mechanism of Action

Dimethyl fumarate is classified as an immunomodulatory agent and an activator of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.

Its proposed therapeutic effects include:

• Anti-inflammatory activity: Modulates immune responses involved in the inflammatory processes associated with multiple sclerosis.
• Neuroprotective effects: Activates cellular pathways involved in responses to oxidative stress.
• Reduction of disease activity: Helps limit inflammatory damage to myelin, the protective covering surrounding nerve fibers, and reduces the development of new MS lesions.

The precise mechanism by which dimethyl fumarate produces its clinical effects in multiple sclerosis is not fully understood.

Dosage and Administration

The following is the usual adult regimen for delayed-release dimethyl fumarate capsules when prescribed for multiple sclerosis:

• Initial dose: 120 mg orally twice daily for 7 days.
• Maintenance dose: 240 mg orally twice daily, starting after the initial 7 days, if tolerated and prescribed.
• Administration: May be taken with or without food; taking it with food may help reduce flushing and gastrointestinal discomfort.
• Swallow the capsules whole. Do not crush, chew, or open them.
• If a dose is missed, follow the instructions in the patient leaflet. Do not double the next dose.

Dosage and administration should be determined by the treating neurologist. Do not initiate, interrupt, or change treatment without medical advice.

Possible Side Effects

Common adverse effects include:

• Flushing, facial redness, warmth, itching, or burning sensations.
• Diarrhea.
• Nausea and vomiting.
• Abdominal pain or discomfort.
• Indigestion.

Serious adverse effects requiring medical attention include:

• Lymphopenia: Reduced lymphocyte counts, which may increase susceptibility to infections.
• Progressive multifocal leukoencephalopathy (PML): A rare, serious opportunistic brain infection associated with JC virus.
• Liver injury, including potentially severe hepatic reactions.
• Serious infections, including herpes zoster (shingles).
• Severe allergic reactions.

Seek urgent medical attention for new or worsening weakness, changes in vision or coordination, confusion, persistent neurological symptoms, jaundice, or signs of a serious infection.

Warnings and Precautions

• Blood monitoring: Obtain a complete blood count, including lymphocyte count, before treatment and periodically during therapy.
• Liver function: Liver enzyme levels and bilirubin should be assessed before treatment and when clinically indicated.
• Infection risk: Inform the physician about active infections, recurrent infections, or a history of shingles.
• Neurological symptoms: New or worsening neurological changes require prompt evaluation for possible PML or disease progression.
• Vaccinations: Discuss vaccination requirements with the treating specialist before and during therapy.
• Pregnancy and breastfeeding: Discuss potential benefits and risks with a healthcare professional before using this medication.
• Drug interactions: Inform the physician about all medications and supplements, particularly other treatments that affect the immune system.
• Allergies: Do not use if there is a known serious hypersensitivity to dimethyl fumarate or any product component.

Regular follow-up with a neurologist is essential to assess treatment response, tolerability, and safety.

Storage

• Store in the original container according to the manufacturer's instructions.
• Protect from excessive heat, moisture, and light as specified in the product leaflet.
• Keep the container tightly closed when required.
• Keep out of the reach and sight of children.
• Do not use after the expiry date.

References

1. MedlinePlus — U.S. National Library of Medicine (.gov): Patient information on indications, administration, precautions, and adverse effects. Read Dimethyl Fumarate Drug Information.
2. U.S. Food and Drug Administration (FDA) (.gov): Prescribing information for Tecfidera (dimethyl fumarate), including approved indications, dosage, warnings, and monitoring. Read FDA prescribing information.
3. National Institutes of Health (NIH) / National Library of Medicine: Official drug-information resources and clinical safety information. Browse drug information.

Patient Disclaimer

This information is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Dimethyl fumarate is a prescription medication that should be used under the supervision of a qualified healthcare professional. Treatment requires appropriate laboratory monitoring and assessment of potential adverse effects. Do not start, stop, or modify treatment without consulting your treating physician. Always read the approved patient leaflet supplied with your medication.